BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302
Debt
Debt-to-Equity Ratio0.35
Current Ratio1.25
Quick Ratio1.25
Price-To-Earnings
Trailing P/E Ratio-9.10
Forward P/E Ratio-7.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.19 million
Price / Sales30.83
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book8.35
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-65,780,000.00
Net Margins-270.95%
Return on Equity-107.85%
Return on Assets-47.69%
Miscellaneous
Employees85
Outstanding Shares109,380,000
Market Cap$798.49 million
BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
How were BioCryst Pharmaceuticals' earnings last quarter?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The biotechnology company earned $12.49 million during the quarter, compared to analysts' expectations of $3.80 million. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. View BioCryst Pharmaceuticals' Earnings History.
When is BioCryst Pharmaceuticals' next earnings date?
What price target have analysts set for BCRX?
8 brokerages have issued 12 month target prices for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $10.0833 in the next year. This suggests a possible upside of 42.0% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.
What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.
What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?
Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (7/10/2018)
- 2. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)
Who are some of BioCryst Pharmaceuticals' key competitors?
Some companies that are related to BioCryst Pharmaceuticals include China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI) and Editas Medicine (EDIT).
Who are BioCryst Pharmaceuticals' key executives?
BioCryst Pharmaceuticals' management team includes the folowing people:
- Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 57)
- Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 50)
- Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 63)
- Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 65)
- Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 51)
Has BioCryst Pharmaceuticals been receiving favorable news coverage?
News articles about BCRX stock have been trending positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a media and rumor sentiment score of 0.28 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 48.98 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for BioCryst Pharmaceuticals.
Who are BioCryst Pharmaceuticals' major shareholders?
BioCryst Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (10.14%), BlackRock Inc. (7.09%), Jennison Associates LLC (3.51%), VHCP Management II LLC (2.25%), Millennium Management LLC (1.55%) and DAFNA Capital Management LLC (0.55%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Fred E Cohen, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.
Which major investors are selling BioCryst Pharmaceuticals stock?
BCRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC, Renaissance Technologies LLC, DAFNA Capital Management LLC, Bank of New York Mellon Corp, Swiss National Bank, ClariVest Asset Management LLC and Jennison Associates LLC. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Fred E Cohen and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.
Which major investors are buying BioCryst Pharmaceuticals stock?
BCRX stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., VHCP Management II LLC, Bank of America Corp DE, Spark Investment Management LLC, State of Wisconsin Investment Board, Paloma Partners Management Co and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for BioCryst Pharmaceuticals.
How do I buy shares of BioCryst Pharmaceuticals?
Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioCryst Pharmaceuticals' stock price today?
One share of BCRX stock can currently be purchased for approximately $7.10.
How big of a company is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a market capitalization of $798.49 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.
How can I contact BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]
MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
